Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Multimodal treatment improves symptoms, survival in stage IV rectal cancer

26 Apr 2020

Multimodal treatment with short-course radiotherapy, systemic therapy, and resection or ablation in stage IV rectal cancer patients results in symptoms relief and is associated with good survival rates among those who are able to complete the schedule, a recent study has shown.

The authors assessed the feasibility and effectiveness of short-course pelvic radiotherapy (5 x 5 Gy) followed by systemic therapy and local treatment of all tumour sites in patients with potentially curable stage IV rectal cancer in daily practice.

This retrospective study was conducted in eight tertiary referral centres in the Netherlands and enrolled patients aged 18 years with rectal cancer and potentially resectable liver ± extrahepatic metastases, treated between 2010 and 2015. Full completion of treatment schedule, symptom control and survival were the main outcomes.

Overall, 169 patients were eligible for analysis, with a median follow-up of 49.5 months (95 percent confidence interval [CI], 43.6–55.6). The completion rate was 65.7 percent for the entire treatment schedule.

Three-year progression-free survival rate was 24.2 percent (95 percent CI, 16.6–31.6), while overall survival (OS) rate was 48.8 percent (95 percent CI, 40.4–57.2). Patients who responded well and completed the treatment schedule had greater median OS than those who did not complete the treatment (51.5 vs 15.1 months; p<0.001).

In addition, 87.0 percent of all patients achieved adequate symptom control of the primary tumour.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.